Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trialGıancarlo Comı, Ludwig Kappos, Bernard M.J. Uitdehaag et al.|The Lancet Neurology|2011Cited by 214